Rani Therapeutics stock target raised
RANI Stock | USD 2.02 0.03 1.51% |
Under 59% of all Rani Therapeutics' traders are looking to take a long position. The analysis of the overall investor sentiment regarding Rani Therapeutics Holdings suggests that some traders are interested. Rani Therapeutics' investing sentiment shows overall attitude of investors towards Rani Therapeutics Holdings.
Rani |
Rani Therapeutics stock target raised
Read at investing.com
Rani Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Rani Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
RANI: 1Q:24 Results
recently @ finance.yahoo.com
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Rani Therapeutics Fundamental Analysis
We analyze Rani Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rani Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rani Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Rani Therapeutics is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Rani Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rani Therapeutics stock to make a market-neutral strategy. Peer analysis of Rani Therapeutics could also be used in its relative valuation, which is a method of valuing Rani Therapeutics by comparing valuation metrics with similar companies.
Peers
Rani Therapeutics Related Equities
CABA | Cabaletta Bio | 26.91 | ||||
SRZN | Surrozen | 19.37 | ||||
GLUE | Monte Rosa | 13.72 | ||||
LYRA | Lyra Therapeutics | 10.53 | ||||
MNPR | Monopar Therapeutics | 8.84 | ||||
TNYA | Tenaya Therapeutics | 8.51 | ||||
VINC | Vincerx Pharma | 7.69 | ||||
BMEA | Biomea Fusion | 3.13 | ||||
VCNX | Vaccinex | 2.44 | ||||
TRVI | Trevi Therapeutics | 2.13 | ||||
PMVP | Pmv Pharmaceuticals | 1.25 | ||||
MOLN | Molecular Partners | 0.17 | ||||
TARA | Protara Therapeutics | 0.99 | ||||
ALXO | Alx Oncology | 1.99 | ||||
TYRA | Tyra Biosciences | 2.00 | ||||
PHVS | Pharvaris | 2.06 | ||||
EYPT | Eyepoint Pharmaceuticals | 2.21 | ||||
CRVS | Corvus Pharmaceuticals | 3.50 | ||||
VIRX | Viracta Therapeutics | 6.67 |
Complementary Tools for Rani Stock analysis
When running Rani Therapeutics' price analysis, check to measure Rani Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rani Therapeutics is operating at the current time. Most of Rani Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rani Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rani Therapeutics' price. Additionally, you may evaluate how the addition of Rani Therapeutics to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |